AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 32 min read$FTRE

Mcconnell Jill G. sold $75K of FTRE

Mcconnell Jill G. (Chief Financial Officer) sold 4,866 shares of Fortrea Holdings Inc. (FTRE) at $15.49 on 2026-06-02.

Original reporting
SEC EDGAR · Mcconnell Jill G.
Published Jun 3, 2026, 8:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 8:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$FTRE
Neutral
low confidence
Mentioned
$FTRE
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FTRENeutralLow
01

Why it matters

Treat as a sentiment/positioning datapoint rather than a fundamental driver; monitor for follow-on filings (additional sales/buys) and any concurrent company news.

02

Market read

A disclosed CFO sale may slightly weigh on short-term sentiment, but it is unlikely to move the stock materially without corroborating fundamental catalysts.

03

What to watch

The article does not state motivations, whether proceeds were for taxes, or whether other insiders/large holders are buying; absence of a 10b5-1 plan detail may increase noise rather than signal.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed June 3 (transaction dated June 2)

Background

The article is an SEC insider transaction disclosure (Form 4) for Fortrea Holdings’ CFO.

Company-level read

Ticker impact

$FTRENeutralLow confidence
Context

Fortrea CFO Jill McConnell sold 4,866 shares in an open-market transaction disclosed via SEC Form 4 on June 2.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional insider activity or fundamentals.

Evidence & confidence

The filing is an ownership-change disclosure with no accompanying company-specific operational or financial news; 10b5-1 plan is explicitly noted as not pre-arranged, but the sale size is not described as material to fundamentals.

Market effects

Sector

Minimal; this is company-specific insider activity without sector-wide implications.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be routine for diversification/taxes and do not necessarily reflect negative expectations.

Key entities

  • issuer
    Fortrea Holdings Inc.

    Subject of the SEC Form 4 insider transaction disclosure.

  • officer
    Jill G. McConnell

    Fortrea CFO who sold shares via open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

FTRE insider trading history →

Related articles

SEP 2
$FTREMed

Fortrea Holdings Inc: Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Fortrea (FTRE) will acquire Worldwide Clinical Trials' Early Phase Services division for $45M, including a bioanalytical lab and clinical pharmacology unit. The deal expands Fortrea's early clinical development capabilities, enhancing its platform for Phases I-IV studies. Worldwide will focus on its late-stage business. The transaction is subject to regulatory approvals.

finanznachrichten.de2 min
JUL 30
$FTREHighAI 9/10

Fortrea Q2 Earnings Call Highlights

"The environment has become more supportive, but our results are not simply the result of market recovery," Thakral said, attributing the performance to changes in commercial execution, including improved global coordination, a sharper focus on opportunities where the company can compete effectively and a clearer approach to serving distinct customer segments. Thakral said Fortrea's clinical pharmacology services business was a particular area of strength.

yahoo.com6 min
JUL 29
$FTREMedAI 8/10

Fortrea (NASDAQ:FTRE) Reports Strong Q2 CY2026, Full

Fortrea Holdings (NASDAQ:FTRE) reported Q2 CY2026 revenue of $678.2 million, down 4.5% year over year but 4.7% above market expectations, according to the company. Full-year revenue guidance was $2.66 billion at the midpoint, 1.8% above analysts’ estimates. Non-GAAP EPS was $0.23, 27.2% above consensus.

financialcontent.com4 min
JUL 29
$FTREMed

Fortrea Holdings Inc. (FTRE): Results of Operations and Financial Condition

Fortrea Holdings Inc. (FTRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fortrea Reports Second Quarter 2026 Results Four consecutive quarters of execution to drive commercial, operational and financial excellence Increases full-year guidance Highlights For the three months ended June 30, 2026: • Revenues of $678.2 million • Book-to-bill

SEC EDGAR 8-K4 min